Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336704 | 0.93 | CARM1 (0.58) | CARM1HRH3PRMT5PNMTHSD17B3 | |
| SCHEMBL6369677 | 0.93 | CARM1 (0.58) | CARM1HRH3PRMT5PNMTHSD17B3 | |
| SCHEMBL1905994 | 0.89 | DRD2 (0.54) | CARM1HRH3PRMT5PNMTHSD17B3 | |
| SCHEMBL578240 | 0.85 | HSD17B3 (0.55) | CARM1PRMT5PNMTHSD17B3ACACB | |
| SCHEMBL7744214 | 0.84 | DRD2 (0.64) | CARM1HRH3PRMT5DRD2DRD3 | |
| SCHEMBL27860421 | 0.82 | CARM1 (0.58) | CARM1PRMT5HSD17B3WDR77ACACB | |
| SCHEMBL6369524 | 0.81 | HRH3 (0.51) | HRH3PRMT5PNMTDRD2DRD3 | |
| SCHEMBL20548499 | 0.80 | CARM1 (0.52) | CARM1HRH3PRMT5DRD2DRD3 | |
| SCHEMBL6369552 | 0.79 | PNMT (0.55) | HRH3PRMT5PNMTWDR77DRD2 | |
| SCHEMBL13171826 | 0.79 | HRH3 (0.50) | HRH3PNMTDRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2014053568-A1 | INDOLYLDIHYDROIMIDAZOPYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, PDXK, HIPK1 | CARM1 2795/4885HRH3 626/4885PRMT5 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.